UNSPSC 51191576: Furosemide sodium

This classification denotes a loop diuretic with the molecular formula C12H10CLN2O5S.NA, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 101EM454S7. European Medicines Agency schedules furosemide sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02287MIG. Most nations, for tariff and trade purposes, schedule furosemide sodium under HS 29350090. As of Q4 2014, FUROSEMIDE SODIUM remains US FDA's Preferred Term for this commodity. SMILES: C1CC(OC1)CNC2CC(C(CC2C(=O)[O-])S(=O)(=O)N)CL.[NA+].

UNSPSC 51191576 Furosemide sodium is a Commodity code that maps poorly to recent state and local procurement activity. The three recent opportunities tagged under this code involve DeZurik/APCO industrial valves and repair services for wastewater treatment (Broward County, Florida), parenteral nutrition and intravenous solutions for correctional healthcare (Washington State Department of Corrections), and sodium bisulfite chemical supply for municipal water treatment (City of Meriden, Connecticut). None of these solicitations concern furosemide, a loop diuretic pharmaceutical. The code appears to be a pharmaceutical-classification placeholder in the UNSPSC structure that does not reflect current state and local buying patterns in these opportunities.

The issuing bodies represent a mix of municipal utilities, state healthcare agencies, and county water management—jurisdictions with ongoing needs for specialized chemicals and medical supplies. No standout repeat buyers appear in the recent record. Activity is geographically scattered across Florida, Washington, and Connecticut with no concentration pattern evident. The Washington State Department of Corrections RFQ (RFQQK13020, due October 7, 2026) is the most substantive opportunity, involving parenteral products and services across eight facilities over a four-year contract term (November 26, 2026–June 30, 2030) with set-aside targets for small, minority-owned, women-owned, and veteran-owned businesses. The scope requires documented experience preparing and delivering IV and total parenteral nutrition solutions within strict time windows and maintaining insurance coverage including cyber liability. Without corroborating evidence of furosemide-specific procurement from state and local bodies, this code warrants close monitoring for category-coding corrections but presents limited targeting opportunity in its current form.